ABOUT US

30 Years, 1000+ Cases

Since 1995, Equinox Group has provided analytics to support R&D decisions at biopharmaceutical firms, assessing the potential of drugs from discovery to launch, and anywhere in between. Our validated techniques will save you time and money, as well as overcome the deficiencies of traditional market research.

We have evaluated thousands of drug profiles across hundreds of indications in oncology, immunology, rare diseases, cardio-metabolic disorders, infectious diseases, neurology, respiratory, urology, ophthalmology, and endocrine disorders. We also have tailored methods to solve the unique analytical challenges that arise in oncology and rare diseases.

Equinox Group specializes in predicting the commercial performance of drug programs in all stages of research and development, delivering quantitative insights regarding: disease area strategy, market access, patient share, patient flow, and epidemiology

Get in touch

Disease-Area Strategy

Find out which indications offer the best commercial opportunities and how to prioritize them

Person writing notes on a transparent glass surface with multicolored markers.

BD & Early R&D

Assess an asset's commercial potential, whether you're evaluating an in-licensing opportunity or developing a TPP

Person in business attire working with financial documents and charts on a tablet at a desk with notebooks, pen, and a yellow mug.

Late-Stage Development

Dive into our patient-share forecasting, patient-flow modeling, and market access tools

Computer screen displaying multiple colorful line graphs showing financial data and trends.

The Unmet Need Framework

Two individuals in formal shirts reviewing handwritten notes and sketches on a notepad, surrounded by open laptops and pens on a wooden table.

Discover the framework at the heart of our analysis and how we use it to predict patient share